Aequus Pharmaceuticals Inc (AQS.CA) Stock Price & Overview
TSX-V:AQS • CA0076361033
Current stock price
The current stock price of AQS.CA is 0.005 CAD. Today AQS.CA is down by 0%. In the past year, price decreased by -80%.
AQS.CA Key Statistics
- Market Cap
- 663.15K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.02
- Dividend Yield
- N/A
AQS.CA Stock Performance
AQS.CA Stock Chart
AQS.CA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to AQS.CA. When comparing the yearly performance of all stocks, AQS.CA is a bad performer in the overall market: 92.41% of all stocks are doing better.
AQS.CA Earnings
AQS.CA Forecast & Estimates
AQS.CA Groups
Sector & Classification
AQS.CA Financial Highlights
Over the last trailing twelve months AQS.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 18.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -311.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AQS.CA Ownership
AQS.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.17 | 2.635B | ||
| CRON | CRONOS GROUP INC | 39.53 | 1.346B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.113B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.57 | 962.125M | ||
| GUD | KNIGHT THERAPEUTICS INC | 128.61 | 607.19M | ||
| WEED | CANOPY GROWTH CORP | N/A | 598.098M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 20.98 | 425.968M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 414.781M | ||
| TSND | TERRASCEND CORP | N/A | 342.258M | ||
| HITI | HIGH TIDE INC | 10.8 | 295.31M | ||
| ACB | AURORA CANNABIS INC | 58.42 | 274.476M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.02 | 267.557M | ||
| XLY | AUXLY CANNABIS GROUP INC | 12.38 | 184.55M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About AQS.CA
Company Profile
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-03-17. The firm is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
Company Info
IPO: 2015-03-17
Aequus Pharmaceuticals Inc
Suite 2820, 200 Granville Street
Vancouver BRITISH COLUMBIA V6C 1S4 CA
CEO: Douglas Glen Janzen
Employees: 12
Phone: 16043367906
Aequus Pharmaceuticals Inc / AQS.CA FAQ
What does Aequus Pharmaceuticals Inc do?
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-03-17. The firm is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
What is the stock price of Aequus Pharmaceuticals Inc today?
The current stock price of AQS.CA is 0.005 CAD.
Does Aequus Pharmaceuticals Inc pay dividends?
AQS.CA does not pay a dividend.
How is the ChartMill rating for Aequus Pharmaceuticals Inc?
AQS.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the Price/Earnings (PE) ratio of Aequus Pharmaceuticals Inc (AQS.CA)?
Aequus Pharmaceuticals Inc (AQS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).
Can you provide the upcoming earnings date for Aequus Pharmaceuticals Inc?
Aequus Pharmaceuticals Inc (AQS.CA) will report earnings on 2025-05-07.